Argenica Therapeutics Limited is an Australia-based biotechnology company, developing novel therapeutics to reduce brain tissue death after stroke and other types of brain injury and neurodegenerative diseases to improve patient outcomes. The Company's lead neuroprotective peptide candidate, ARG-007, has been demonstrated to improve outcomes in pre-clinical stroke models, traumatic brain injury (TBI) and hypoxic ischemic encephalopathy (HIE). The Company has initiated a Phase 2 clinical trial in acute ischemic stroke patients, as well as continuing to generate preclinical data in other neurological conditions.
Argenica Therapeutics seeks trading halt
By Reuters